Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.
Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.
Our news collection prioritizes accuracy and timeliness, offering:
• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news
Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing therapeutics for anxiety, depression, and addiction, announced participation in the Benzinga Psychedelics Capital Conference on April 13, 2023. CEO
Dr. Tucker aims to showcase Enveric's clinical development strategy, including the upcoming Phase 1 study of lead candidate EB-373 in Australia.
Enveric Biosciences (NASDAQ: ENVB) announces significant developments in their pipeline targeting mental health disorders. They've nominated EB-373 as the lead candidate for treating anxiety disorders, advancing from their EVM201 Series. A Phase 1 clinical trial is set to start in Q4 2023 in Australia, utilizing the contract research organization, Avance Clinical. Financially, the company reported a $19.3 million net loss for 2022, an improvement from the previous year's $48.8 million. The company also plans a spin-off of its cannabinoid pipeline to Akos Biosciences, Inc.. Overall, Enveric is poised for an active 2023, targeting innovations in mental health therapies.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
